During March, $JNJ-61186372 / amivantamab was granted Breakthrough Therapy Designation by the FDA, in NSCLC with EGFR Exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy. (source $GMAB) https://t.co/1lKa5dptoL